Clinical trial · Observational
Treatment of Leukemia and Lymphoma in Children With Ataxia Telangiectasia
Treatment of Leukemia and Lymphoma in Children With Ataxia Telangiectasia- A Retrospective Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Ataxia telangiectasia (A-T) is a multisystem disease with diverse manifestations, including progressive neurodegeneration, immunodeficiency, respiratory disease, and genomic instability. One of the most important features of A-T is the increased predisposition to cancer, especially to lymphoid malignancies. Patients with A-T are generally excluded from collaborative clinical trials, their treatment outcomes and toxicity profiles have rarely been reported, and little is currently known concerning the treatment intensity required to provide a reasonable balance between efficacy and toxicity. The aims of this study are to build a large international de-identified database of children with A-T treated for leukemia and lymphoma, to investigate epidemiology and outcome of treatment, toxicity profiles and risk factors which impact outcome, in order to eventually enable the generation of data-based treatment recommendations for this population.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (5)
- measure
- Event-free survival
- timeFrame
- 5 years
- description
- Assess 5 and 3-year event-free survival
- measure
- Overall survival
- timeFrame
- 5 years
- description
- Assess 5 and 3-year overall survival
- measure
- Cumulative incidence of relapse
- timeFrame
- 5 years
- description
- Assess 5-year cumulative incidence of leukemia/lymphoma relapse
- measure
- Cumulative incidence of treatment-related mortality
- timeFrame
- 2 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 0 Years
- Maximum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria: * Individuals diagnosed with ataxia telangiectasia and leukemia or lymphoma * Age 0-21 Exclusion Criteria: -Age greater than 21 years
References
Publications (0)
Data not yet available